Friday 6 November 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS: −61.5%
Free cash flow: −92.6%

Quarter to June 2026, against a year earlier

64.10 2.18 +3.52%

Follow PCVX

Alert me

Market cap: $9.8B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Vaxcyte, Inc. 10-Q filed Nov 5, 2024

Fiscal Q3 2024 · Period ended Sep 30, 2024 · Filed Nov 5, 2024 · accepted 4:05 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov